Evidence map›Paper›PMID 30378723›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2019

Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.

Allison J Kwong, Anji Wall, Marc Melcher, Uerica Wang, Aijaz Ahmed, Aruna Subramanian, Paul Y Kwo

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04596475 (Prevention of Transmission of Hepatitis C Virus), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04596475 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor to HCVNegative Organ Transplant Recipient - Pilot Trial

TypeinterventionalSponsorUniversity of California, San DiegoRan2021 to 2022Enrolled12ConditionsHepatitis C, Hepatitis C Virus Infection, Response to Therapy ofArmsglecaprevir/pibrentasvir (GLE/PIB)
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  4. Trends in candidate hepatitis C virus nucleic acid amplification test (NAT)+ listing and associated impacts on liver transplantation waitlist outcomes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Breakthroughs in hepatitis C research: from discovery to cure.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Allison J KwongDivision of Gastroenterology and Hepatology, Stanford University, Stanford, California.ORCID 0000-0002-3874-6612
Anji WallDepartment of Surgery, Stanford University, Stanford, California.
Marc MelcherDepartment of Surgery, Stanford University, Stanford, California.ORCID 0000-0002-7185-4383
Uerica WangDepartment of Pharmacy, Stanford Hospital and Clinics, Stanford, California.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University, Stanford, California.
Aruna SubramanianDivision of Infectious Diseases, Stanford University, Stanford, California.
Paul Y KwoDivision of Gastroenterology and Hepatology, Stanford University, Stanford, California.
Stanford University · USBaylor University Medical Center · USStanford Health Care · USUniversity of California, San Francisco · US

Funding

TRAINING GRANT IN ACADEMIC GASTROENTEROLOGYT32DK007056 · NIDDK · STANFORD UNIVERSITY · PI Natalie J. Torok · 1986 to 2026
$6.5M
Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
NCATS NIH HHS KL2 TR001083NIDDK NIH HHS T32 DK007056
6 · The paper itself

Abstract

In the context of organ shortage, the opioid epidemic, and effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more HCV-infected donor organs may be used for liver transplantation. Current data regarding outcomes after donor-derived HCV in previously non-viremic liver transplant recipients are limited. Clinical data for adult liver transplant recipients with donor-derived HCV infection from March 2017 to January 2018 at our institution were extracted from the medical record. Ten patients received livers from donors known to be infected with HCV based on positive nucleic acid testing. Seven had a prior diagnosis of HCV and were treated before liver transplantation. All recipients were non-viremic at the time of transplantation. All 10 recipients derived hepatitis C infection from their donor and achieved sustained virologic response at 12 weeks posttreatment with DAA-based regimens, with a median time from transplant to treatment initiation of 43 days (IQR 20-59). There have been no instances of graft loss or death, with median follow-up of 380 days (IQR 263-434) posttransplant. Transplantation of HCV-viremic livers into non-viremic recipients results in acceptable short-term outcomes. Such strategies may be used to expand the donor pool and increase access to liver transplantation.

Indexed as

Postoperative ComplicationsAdultAgedAntiviral AgentsFemaleFollow-Up StudiesGraft SurvivalHepacivirusHepatitis CHumansLiver TransplantationMaleMiddle AgedPrognosisRisk FactorsTissue and Organ ProcurementAntiviral Agentsclinical research/practiceliver allograft function/dysfunctionliver diseaseliver transplantation/hepatologyorgan acceptance

Identifiers

PMID30378723
PMCPMC6663314
OpenAlexW2899207096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.